N/A N=39 A Physical Activity Program to Disrupt Sedentary Time in Older Latinos
Sedentary Behavior · Cognitive Impairment
Primary: Number of Sedentary Bouts — -11.58; -2.47 Sedentary bouts
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=68 Clinical Performance of Masimo Rad-GT
Healthy
Primary: Accuracy of Masimo Rad-GT Temperature Measurements (Degrees Celsius) — -0.24; 0.85; 0.04 Degrees Celsius
N/A N=12 Attention Control Training (ACT) and Very Preterm Infants
Very Premature Baby
Primary: Recruitment and Retention — 5; 5 Participants
Phase 2 N=28 Mild Encephalopathy in the Newborn Treated With Darbepoetin
Neonatal Encephalopathy · Hypoxic-Ischemic Encephalopathy Mild
Primary: Normal Neurodevelopment — 13; 14 Participants
Phase 3 N=162 HEALEY ALS Platform Trial - Regimen A Zilucoplan
Amyotrophic Lateral Sclerosis
Primary: Disease Progression as Assessed by the ALSFRS-R Total Score — -1.11; -1.03 ALSFRS-R total score points per month
Phase 1 N=8 Validation of the Drug Impaired Driving Scenario (DIDS) on the CRCDS-miniSim
Driving Behavior · Driving Under the Influence
Primary: Standard Deviation of Lateral Position (SDLP) — 25.490; 37.849; 33.086 cm
Phase 3 N=161 HEALEY ALS Platform Trial - Regimen C CNM-Au8
Amyotrophic Lateral Sclerosis
Primary: Disease Progression as Assessed by the ALSFRS-R Total Score — -1.01; -1.03 ALSFRS-R total score points per month
N/A N=170 Emervel Classic Lidocaine Versus Juvederm® Ultra in Treatment of Moderate to Severe Facial Wrinkles and Folds
Skin Wrinkling
Primary: Mean Change From Baseline in Wrinkle Severity Rating Scale (WSRS) at Week 24 After Final Initial Injection — -1.1; -1.2 Score on a scale
Phase 2 N=142 Impact of Colchicine and Low-dose Naltrexone on COVID-19
Covid19
Primary: In Patients Hospitalized With Moderate COVID-19, the Impact of Colchicine and LDN, Alone or in Combination, on Achieving Disease Recovery by Day 5. — 22; 24; 20; 18…
Phase 4 N=60 ECT Pulse Amplitude and Medial Temporal Lobe Engagement
Major Depressive Disorder
Primary: Depression Severity — 22.5; 12.0; 14.1 score on a scale — p=0.04
Phase 3 N=1,591 A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine
Migraine · Migraine With Aura · Migraine Without Aura
Primary: Percentage of Subjects With Freedom From Migraine Headache Pain at 2 Hours Post Dose — 146; 124 Participants
Phase 3 N=86 Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)
Paroxysmal Nocturnal Hemoglobinuria
Primary: Change From Baseline in Hgb at Week 12 — 29.40; 4.96; 28.08; 4.62 g/L — p=0.0007
Phase 1 N=22 Interactions Between Cannabinoids and Cytochrome P450-Metabolized Drugs
Drug-Interactions
Primary: Losartan Area Under the Curve (AUC) in Plasma — 164; 185; 289 h*ng/mL
Phase 4 N=110 Nifedipine XL Versus Placebo for the Treatment of Preeclampsia With Severe Features During Induction of Labor
Preeclampsia Severe
Primary: Number of Participants With the Change in Blood Pressure (Both Systolic and Diastolic) Under the Treatment of NIfedipine 30mg XL Versus Placebo — 18; 27 Participants
Phase 3 N=1,330 P3 Study Comparing Once Daily SB204 and Vehicle Gel in Acne
Acne Vulgaris
Primary: Absolute Change From Baseline in Inflammatory Lesion Counts — -13.1; -10.9 inflammatory acne lesions